Overview

Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

Status:
Not yet recruiting

Trial end date:
2022-11-29

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effect of various degrees of hepatic impairment on plasma pharmacokinetics (PK), safety and tolerability of TNO155. The results of this study will guide the Novartis recommendation regarding whether or not a dose adjustment may be needed when treating patients with hepatic impairment.

Phase:

Phase 1

Details

Lead Sponsor:

Novartis Pharmaceuticals

Collaborator:

Pharmaceutical Research Associates